Johnson & Johnson (JNJ)Officer sold ~$3.13M

~$3.13M

Approx. value · 19K sh @ $163.55

11K

Holds after · shares reported

Traded

Jul 17, 2025

Filed

Jul 18, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Mar 15, 2023CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
2. Aug 7, 2024CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
3. Sep 26, 2024CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
4. Oct 29, 2024CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
5. Mar 19, 2025CongressDisclosed sale of JNJ — reported range $15,001 - $50,000
6. May 12, 2025CongressDisclosed sale of JNJ — reported range $50,001 - $100,000
7. May 30, 2025CongressDisclosed purchase of JNJ — reported range $15,001 - $50,000
8. Jun 10, 2025CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
9. Jun 12, 2025CongressDisclosed sale of JNJ — reported range $15,001 - $50,000
10. Jun 16, 2025CongressDisclosed sale of JNJ — reported range $15,001 - $50,000
11. Jun 17, 2025CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
12. Jun 24, 2025CongressDisclosed sale of JNJ — reported range $1,001 - $15,000
13. Jul 17, 2025 · this disclosureInsiderOfficer sold ~$3.13M of JNJ shares in the open market

What came next

1. Jul 31, 2025CongressDisclosed partial sale of JNJ — reported range $15,001 - $50,000
2. Aug 4, 2025Congress · 1 personMembers of Congress: 2 purchases
3. Aug 14, 2025CongressDisclosed partial sale of JNJ — reported range $1,001 - $15,000
4. Aug 15, 2025InsiderCFO sold ~$2.98M of JNJ shares in the open market
5. Aug 19, 2025CongressDisclosed partial sale of JNJ — reported range $1,001 - $15,000
6. Aug 22, 2025InsiderCEO sold ~$22.5M of JNJ shares in the open market
7. Sep 4, 2025Insider · 4 days before an 8-KOfficer sold ~$10M of JNJ shares in the open market
8. Sep 8, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On September 8, 2025, Johnson & Johnson (the Company) announced that John Morikis was elected to the Board of Directors. The Board has determined that Mr. Morikis satisfies the applicable independence requirements of the NYSE Listed Company Manual.”
9. Sep 9, 2025FDAFDA drug approval: Inlexzo
10. Sep 11, 2025FDARecall: ECHELON LINEAR Cutters Reload 80 mm Blue, intended for transection, resection, and/or creation of anastomoses, Product Number GLC80
11. Sep 16, 2025FDARecall: Automated Impella Controller (AIC) labeled as the following with corresponding Product Codes: 1. AIC w/Impella Connect for ECP, Product Code: 1000432. 2. Dbl o…
12. Sep 19, 2025FDAFDA drug approval: Tremfya
13. Sep 23, 2025CongressDisclosed sale of JNJ — reported range $1,001 - $15,000
14. Sep 26, 2025FDAFDA drug approval: Tremfya
15. Sep 26, 2025FDAFDA drug approval: Tremfya
16. Sep 26, 2025FDARecall: LOW PROF LCKNG SCREW, F/IM NAIL 5.0MM / L, 42MM / XL25/ STER. Product Code: 04.045.342TS. Used in RFN-ADVANCEDTM Retrograde Femoral Nailing (RFNA) System and t…
17. Sep 26, 2025FDARecall: LOW PROF LCKNG SCREW, F/IM NAIL 5.0MM / L, 46MM / XL25/ STER. Product Code: 04.045.346TS. Used in RFN-ADVANCEDTM Retrograde Femoral Nailing (RFNA) System and t…
18. Oct 1, 2025FDARecall: Automated Impella Controller (AIC), used for left heart support blood pump, labeled as the following with corresponding Product Codes: 1. Impella Controller, P…
19. Oct 8, 2025FDAFDA device clearance: 14Fr Low Profile Introducer Kit
20. Oct 9, 2025Federal contract · $19K obligatedDepartment of Veterans Affairs awarded Johnson & Johnson: $19K obligated to date

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Johnson & Johnson

For Johnson & Johnson, OQRO holds 15 insider filings (SEC Form 4 or Form 144), 8 Congress trade reports, 167 fund holdings reports (13F) and 5 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its JNJ page.

Other recent filings by John C Reed, EVP, Innovative Medicine, R&D

• SEC Form 4 at Johnson & Johnson (JNJ)Feb 19, 2026
• SEC Form 4 at Johnson & Johnson (JNJ)Feb 19, 2026
• SEC Form 4 at Johnson & Johnson (JNJ)Feb 19, 2026
• SEC Form 4 at Johnson & Johnson (JNJ)Oct 20, 2025

The full history of John C Reed, EVP, Innovative Medicine, R&D is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Johnson & Johnson

• House Clerk periodic transaction reportOct 5, 2026
• USAspending.gov award recordOct 5, 2026
• USAspending.gov award recordSep 22, 2026
• USAspending.gov award recordSep 21, 2026
• House Clerk periodic transaction reportSep 12, 2026
• Senate eFD periodic transaction reportSep 11, 2026

Everything OQRO holds on this company is on its JNJ page.